Cochrane · systematic review · CD008218
Anti‐angiogenic therapy for high‐grade glioma
Ameratunga, M, Pavlakis, N, Wheeler, H, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 2 · 25%High 5 · 62.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anti‐angiogenic therapy compared to no anti‐angiogenic therapy for high‐grade glioma (HGG)
Population: people with HGG
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival ( Anti‐angiogenic therapy vs no anti‐angiogenic therapy | HR 0.95 [0.88, 1.02] | 11 studies · 3743 participants | High |
Progression‐free survival ( Anti‐angiogenic therapy vs no anti‐angiogenic therapy | HR 0.73 [0.68, 0.79] | 10 studies · 3595 participants | High |
Anti‐angiogenic therapy compared to no anti‐angiogenic therapy for high‐grade glioma (HGG), subgroups
Population: people with HGG
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival ( Anti‐angiogenic therapy vs no anti‐angiogenic therapy | HR 0.93 [0.86, 1.02] | 8 studies · 2833 participants | High |
Overall survival ( Anti‐angiogenic therapy vs no anti‐angiogenic therapy | HR 0.99 [0.85, 1.16] | 3 studies · 910 participants | Moderate Downgraded: inconsistency |
Overall survival ( Anti‐angiogenic therapy vs no anti‐angiogenic therapy | HR 0.92 [0.85, 1] | 11 studies · 3506 participants | Low Downgraded: imprecision, inconsistency |
Progression‐free survival ( Anti‐angiogenic therapy vs no anti‐angiogenic therapy | HR 0.75 [0.69, 0.82] | 8 studies · 2833 participants | High |
Progression‐free survival ( Anti‐angiogenic therapy vs no anti‐angiogenic therapy | HR 0.64 [0.54, 0.76] | 2 studies · 762 participants | Moderate Downgraded: imprecision, inconsistency |
Progression‐free survival ( Anti‐angiogenic therapy vs no anti‐angiogenic therapy | HR 0.72 [0.66, 0.77] | 10 studies · 3464 participants | High |